China Molecular Diagnostics Market will be US$ 6.3 Billion by 2026

According to the latest report by Renub Research, titled “China Molecular Diagnostics Market & Volume Forecast, by Application [Oncology Testing, Infectious Disease Testing, and Genetic Disease Testing]” China is one of the largest clinical laboratory markets in the Asia-Pacific region and one of the fastest-growing molecular diagnostics markets. The China Molecular Diagnostics Market is forecasted to expand significantly in the future, owing to the increase in the geriatric population & the growing prevalence of chronic diseases such as diabetes, cancer, and CVD diagnosed and monitored with medical devices. According to a 2017 United Nations survey, China is on the brink of an elderly population crisis, with the elderly population projected to hit 25% by 2030. China Molecular Diagnostics Market is forecasted to be US$ 6.3 Billion by 2026.

Molecular diagnostic tests that find specific DNA or RNA sequences may or may not be related to a disease (such as single nucleotide polymorphisms (SNPs), deletions, rearrangements, insertions, and others). Molecular diagnostics is still in its early stages of growth in this Asian country. The majority of molecular diagnostic systems are “open,” with instruments supplied by multinational life science firms in China.

China molecular diagnostics market is segmented into 3 main categories: Genetic Disease Test, Oncology Test, and Infectious Disease Test.

Oncology examinations are further classified into three categories: Colorectal Cancer, Prostate Cancer, and Breast Cancer. Infectious Disease Studies are classified into two categories: HPV and virology. HLA and Blood Screening are two forms of genetic testing. In China’s molecular genetic testing industry, blood screening tests are the most common. According to Renub Research analysis, China will conduct nearly 441 million molecular diagnostic tests by the end of 2026, with virology being one of the most common test segments.

The Effect of Coronavirus on the Molecular Diagnostics Industry

Furthermore, COVID-19 has catalyzed China’s diagnostics industry. The Chinese government is performing a large number of COVID experiments in order to control the spread of disease. RT-PCR and quick neutralizer tests, also known as serological tests, are two types of tests used to classify the COVID illness. The cutting-edge test RT-PCR is known as having the “highest quality standard.” The procedure is completed by collecting a nasal/throat swab from the patient. This test involves extracting ribonucleic acid corrosive, or RNA, which is the infection’s inherited material. This is a costly test that necessitates RNA extraction devices, a testing facility, and trained staff. On the other hand, fast counteracting agent tests are adaptable, guided nearby, provide quick results, and are cost-effective.

Request a Free Sample Copy of the Report:https://www.renub.com/request-sample-page.php?gturl=china-molecular-diagnostics-market-test-volume-and-forecast-491-p.php

Market Summary:

By Application: The report studies the market and volume of the following segments in Molecular Diagnostics: Oncology Testing (Colorectal Cancer, Breast Cancer, Prostate Cancer), Infectious Disease Testing (HPV, Virology), and Genetic Disease Testing (HLA and Blood Screening).

By Company: Profiles of Private Clinical Labs and Diagnostic Services Companies in China of the following Companies such as Guangzhou Kingmed Diagnostics Center Co. Ltd., OriGene Technologies (Privately held), Zhejiang Di’an Diagnostics Technology Co., Ltd, Kindstar Global, ADICON Clinical Laboratories, BGI-Shenzhen.


About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building and Construction, & Agriculture. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Our core team is comprised of experienced people holding graduate, postgraduate and PhD degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research helps to make business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them with findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today’s ultra-competitive markets.

Contact Us:
Renub Research
Phone No: +1 678–302–0700 (USA) | +91–120–421–9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research

China Molecular Diagnostics Market Analysis Report by Renub Research

Molecular diagnostics plays an important role in the identification of diseases and has gained more public & healthcare specialist attention than ever before. The molecular diagnostics is a technique used for the molecular biological detection of any change in the structure or expression of a patient’s genetic material. According to Renub Research, China Molecular Diagnostics Market is expected to be US$ 6.3 Billion by 2026.

In recent years, Molecular diagnostics has changed the face of clinical laboratories by offering easy to use automated molecular systems that provide rapid results with less hands-on time. However, huddles for China diagnostic companies are Lack of Government Support, Public Awareness for Molecular Diagnostics test.

China Molecular Diagnostics Market & Volume Forecast, by Application

COVID-19 effect on Molecular Diagnostics Industry

Besides, COVID-19 has worked as a catalyst for molecular diagnostics industry in China. In order to spread the disease government of China is doing massive number of COVID test. The types of tests which are done to indentify the coronavirus disease are RT-PCR, and rapid anti-body tests also known as serological tests. RT-PCR is considered the ‘gold standard’ frontline test. In this test testing is done by taking a nasal/throat swab from a patient. This test involves extracting ribonucleic acid or RNA, which is the genetic material of the virus. This is a fairly expensive test it requires RNA extracting machines, a laboratory and trained technicians. On the other hand rapid anti-body tests are portable, administered on-site, provide quick answers and are inexpensive too.

China molecular diagnostics market is segmented into three main categories: Oncology Test, Infectious Disease Test and Genetic Disease Test. Further, Oncology Test has been segmented into three types: Prostate Cancer, Colorectal Cancer and Breast Cancer. Infectious Disease Test has been further categorized into two main types, which is virology and HPV. Genetic Test has been categorized into HLA and Blood Screening. Blood screening test is a dominating segment in the China molecular genetic testing market. According to Renub Research analysis nearly 441 million molecular diagnostic tests will be performed in China by the end of 2026 of which Virology accounts for one of the most performed tests segments.

DICON Clinical Laboratories, Zhejiang Di’an Diagnostics Technology Co., Ltd, Kindstar Global, BGI-Shenzhen, A, Guangzhou Kingmed Diagnostics Center Co. Ltd and OriGene Technologies holds majority of market share in China. However, restriction on export is expected to have minimal impact on the manufacturers as the demand is very high in China which is creating a robust revenue pool for manufacturers dealing in the molecular diagnostics sector.

Renub Research report titled “China Molecular Diagnostics Market, Volume, by Application [Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV), and Genetic Disease Testing (Blood Screening, HLA)]” provides a complete analysis of China Molecular Diagnostics Market.

By Application

The report studies the market and volume of the following segments in Molecular Diagnostics: Infectious Disease Testing (Virology, HPV), Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), and Genetic Disease Testing (Blood Screening, HLA).

Request a free Sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=china-molecular-diagnostics-market-test-volume-and-forecast-491-p.php

Segment Covered in this report are as follows:

Oncology Testing Market and Volume

• Breast Cancer
• Colorectal Cancer
• Prostate Cancer

Infectious Disease Testing Market and Volume

• Virology
• HPV

Genetic Testing Market and Volume

• Blood Screening
• HLA

Profiles of Private Clinical Labs and Diagnostic Services Companies in China

• Zhejiang Di’an Diagnostics Technology Co., Ltd
• ADICON Clinical Laboratories
• Guangzhou Kingmed Diagnostics Center Co. Ltd.
• Kindstar Global (Privately held)
• BGI-Shenzhen (Privately held)
• OriGene Technologies (Privately held)

Industry Related Opportunity:

Japan In Vitro Diagnostics (IVD) Market: https://www.renub.com/japan-in-vitro-diagnostics-market-p.php

Global Molecular Diagnostics Market: https://www.renub.com/global-molecular-diagnostics-market-and-future-forecast-2010-2014-334-p.php

About Company:

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research